Overall Survival With First-Line Palbociclib Plus Letrozole vs Placebo Plus Letrozole in Women With ER+/HER2− Advanced Breast Cancer
Journal of Clinical Oncology
TAKE-HOME MESSAGE
This updated overall survival (OS) analysis of the PALOMA-2 trial showed that, after a median follow-up period of 90 months, palbociclib plus letrozole resulted in a numerically, but not statistically significant, longer OS compared with letrozole alone for the first-line treatment in postmenopausal women with ER+/HER2− advanced breast cancer (ABC).
Palbociclib is the only CDK4/6 inhibitor that did not demonstrate an OS benefit in the first-line setting in patients with ER+/HER2− ABC.
– Jing Xi, MD, MPH
Written by
Hazelgreen
To view profiles and participate in discussions please or .
"median OS (95% CI) was 53.9 months (49.8–60.8) in the PAL+LET arm and 51.2 months (43.7 –58.9) in the PBO+LET arm (hazard ratio, 0.956 [95% CI, 0.777–1.177]; stratified 1-sided P=0.3378)"
Clearly, Susan, at 60 months, you are in the more successful 50% (top half of the median). I'm sure there are many women from the original study still going strong!
In fact, with 60 months progression-free survival, Susan is way outperforming the median 24.8 month median PFS from their drug trial. Go Susan! SO INSPIRING to hear real world evidence of these drugs working so well. There aren't great statistics available of how long women are surviving with mbc.
That’s wonderful to hear- how many mg of Ibrance are you on? I am just starting on anastronole(letrozole) and having severe nausea and diareahh - supposed to start Ibrance/ I hope I can do it and have success like you - Side effects hopefully subside
I am on 125 mg Ibrance since April 2017. I have minimal side effects probably from the letrozole. My hands have joint pain and by bedtime I am exhausted but I go strong all day.
Are you taking anastrazole or letrozole? I had an allergic reaction to letrozole, and other side effects, so onc switched me to anastrazole, which I tolerate much better.
In addition to OS, PFS (progression free survival) is very important. It’s not always coincide with OS. PFS in PALOMA-2 was statistically significant leading to approval, but OS reported after 90-month follow-up is not. It’s also important to note that this is a data from the follow-up of the patients enrolled years ago in the original clinical study. It’d be interesting to know the results from the real world data. I’m sure Pfizer will provide that to support the approval.
When I was first diagnosed with MBC my original oncologist wanted to put me on Verzenio as she said that there was no survivorship data about Ibrance. Since I was moving the following month to another state I did not start on anything. When I came to Florida, my oncologist here recommended Ibrance and said there was survivorship data. I am on 125mg Ibrance with letrozole since November of 2020. So far so good. The only side effect is hair thinning and some loss and loss of eyelashes and eyebrows. I feel great otherwise. I really did not want to have the diarrhea that Verzenio can cause as I dealt with issues like that for many, many years as a teenager and young adult due to stressed induced IBS and it was not fun! I am hoping to stay on this combo for a long time, so it is great to see that Susan1953 has been on this combo for over 5 years. I would be extremely happy to do that as well!
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Latest Details on Approval of Oral SERDS - In Place of Faslodex Shots
